CPT 54405, in plain terms, covers Surgically placing a multi-part artificial penis device to restore function or appearance. CPT 54405 is referenced in 5 tracked payer policy changes from Sentara Health Plans, Excellus BlueCross BlueShield, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 54405 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Official descriptor: CPT 54405 on AAPC
Starting January 1, 2027, Sentara Health Plans will require prior authorization for a long list of codes on Virginia commercial plans, including self-funded (ASO) plans, and for code 88380 on commercial, Medicaid and Medicare products, plus code 22860 on Medicare products. Sentara will also stop covering a separate list of codes on Virginia commercial and self-funded plans.
Excellus BlueCross BlueShield medical policy 7.01.30 sets the criteria for treating erectile dysfunction (ED). Treatment is considered medically appropriate when symptoms have lasted more than six months and one of the listed modalities applies: oral drug therapy, intracavernous injection therapy, the transurethral MUSE system, vacuum constriction devices, penile prosthetic implants, or arterial revascularization. Treatment may start before six months for an acute event such as penile trauma or radical pelvic surgery, or for drug-induced ED caused by treatment of a co-morbid condition. The 10/22/26 revision is an annual review, and the policy intent is unchanged.
This is a revised Medicare Advantage policy (effective 08/03/2026) clarifying coverage criteria for penile prosthesis implants for erectile dysfunction. The policy establishes specific medical necessity requirements including comprehensive history/exam, documented failure of conservative management, and 6-month persistence of ED. Additionally, the policy explicitly excludes coverage for vacuum erection devices, stem cell therapy, and shockwave therapy (LI-ESWT) due to insufficient evidence.
Policy 7.01.84 sets the criteria for gender affirming surgery and treatments for commercial and Medicare Advantage members, with a current effective date of May 21, 2026. Gender affirming surgery may be considered medically necessary when the member has reached age 18 (except for mastectomy), one letter from a qualified professional documents gender dysphoria that is marked and sustained for at least 6 months, and the other general criteria are met. Breast augmentation, hysterectomy, gonadectomy and genital reconstructive surgery each require six months of continuous hormone therapy or a documented contraindication to hormone therapy, and voice modification and voice therapy require review by a Health Plan Behavioral Health Medical Director.
Effective January 22, 2026, gender reassignment surgery is considered medically appropriate for members age 18 or older who have referral letters from two qualified NYS licensed health professionals, and the policy lists the covered surgeries and services for Medicaid Managed Care Plan and Health and Recovery Plan members. The January 22, 2026 annual review moved the hormone therapy criteria to Pharmacy policies with policy intent unchanged, and a March 20, 2026 policy edit revised policy statement references for alignment, also with intent unchanged.
Watch 54405
Get one email when a payer policy names 54405, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for 54405
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for 54405 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.